Pfizer (PFE) has entered into an agreement with Boltz to use the latter’s biomolecular AI foundation models to tap into the former’s historical data “to create state-of-the-art, exclusive models for structure prediction, small-molecule affinity, and biologics design.”
Boltz will also build custom models and workflows for several target programs, “aiming to accelerate and enhance decision-making in preclinical programs,” according to a news release.
Pfizer retains all rights to any compounds discovered with Boltz’s models. Financial terms were not disclosed.
